HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

pegvisomant

is a genetically engineered analogue of human growth hormone that functions as a growth hormone-receptor antagonist; used to treat Acromegaly;
Also Known As:
B-2036 PEG; B2036-PEG; Somavert
Networked: 322 relevant articles (65 outcomes, 67 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1. Trainer, P J: 22 articles (04/2012 - 04/2000)
2. van der Lely, A J: 18 articles (04/2017 - 04/2000)
3. Drake, W M: 15 articles (04/2012 - 04/2000)
4. Brue, Thierry: 13 articles (06/2022 - 01/2009)
5. Neggers, Sebastian J C M M: 12 articles (06/2020 - 12/2007)
6. Parkinson, C: 12 articles (11/2006 - 04/2000)
7. Colao, A: 11 articles (08/2022 - 01/2000)
8. Strasburger, Christian J: 11 articles (01/2019 - 10/2003)
9. Bidlingmaier, M: 11 articles (08/2013 - 04/2000)
10. Trainer, Peter J: 11 articles (11/2009 - 01/2002)

Related Diseases

1. Acromegaly
2. Insulin Resistance
3. Neoplasms (Cancer)
4. Pituitary Neoplasms (Pituitary Adenoma)
5. Hypertension (High Blood Pressure)

Related Drugs and Biologics

1. Insulin-Like Growth Factor I (IGF-1)
2. Somatostatin (Somatotropin Release-Inhibiting Factor)
3. Somatotropin Receptors (Growth Hormone Receptor)
4. Octreotide (Sandostatin)
5. Cabergoline
6. Glucose (Dextrose)
7. Dopamine Agonists (Dopamine Agonist)
8. pegvisomant
9. Insulin (Novolin)
10. lanreotide (Somatuline)

Related Therapies and Procedures

1. Therapeutics
2. Drug Therapy (Chemotherapy)
3. Radiotherapy
4. Glycemic Control
5. Injections